8-K: GRI Bio Announces 1-for-13 Reverse Stock Split to Regain Nasdaq Compliance

GRI Bio has announced a 1-for-13 reverse stock split of its common stock, effective June 17, 2024, to increase its share price and regain compliance with Nasdaq's minimum bid price requirement.

Summary

• GRI Bio, Inc. has implemented a 1-for-13 reverse stock split of its common stock.
• The reverse stock split was approved by stockholders on June 7, 2024.
• The split will be effective at 4:01 p.m. Eastern Time on June 17, 2024.
• Trading on a post-split basis will begin on The Nasdaq Capital Market on June 18, 2024.
• Every 13 shares of common stock will be converted into 1 share.
• The number of outstanding shares will decrease from approximately 6,605,271 to approximately 508,091.
• The total authorized number of shares will not be reduced.
• Fractional shares will be paid out in cash based on the closing price on June 17, 2024.
• Proportional adjustments will be made to stock options, warrants, and convertible securities.
• The new CUSIP number for the common stock will be 3622AW 304.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the necessity of a reverse stock split to maintain Nasdaq listing, which suggests underlying financial challenges. However, the company is taking proactive steps to address the issue.

Positives

• The reverse stock split is a strategic move to regain compliance with Nasdaq listing requirements.
• The company is taking proactive steps to maintain its listing on The Nasdaq Capital Market.
• The reverse stock split will not change the total authorized number of shares.

Negatives

• The reverse stock split reduces the number of outstanding shares, which may be perceived negatively by some investors.
• The company is required to take this action due to its share price falling below the Nasdaq minimum bid price.

Risks

• The company may not be able to maintain the listing of its common stock on Nasdaq.
• The company faces risks related to raising future financing.
• There are risks associated with the success, cost, and timing of the company's product development activities.
• The company may not be able to obtain regulatory clearance or approval for its products.
• The company faces competition from other companies in the market.
• The company's estimates regarding expenses, future revenue, and capital requirements may be inaccurate.
• The company may not be able to protect and enforce its intellectual property portfolio.

Future Outlook

The company aims to regain compliance with the Nasdaq minimum bid price requirement through the reverse stock split. The company continues to develop its pipeline of NKT cell modulator therapies.

Management Comments

• The board of directors of the Company approved a 1-for-13 reverse stock split.
• The reverse split is intended to increase the per share trading price of the Company's common stock to enable the Company to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.

Industry Context

Reverse stock splits are a common strategy for companies facing delisting from major exchanges due to low share prices. This action is often a sign of financial challenges and is not unique to GRI Bio in the biotechnology sector.

Comparison to Industry Standards

• Many biotechnology companies, particularly those in the clinical stage, have faced similar challenges with maintaining share price compliance on major exchanges.
• Reverse stock splits are a common mechanism used by companies to avoid delisting, with the goal of attracting institutional investors and improving market perception.
• Companies like Agenus Inc. and Cellectar Biosciences have also recently implemented reverse stock splits to maintain their Nasdaq listings.
• The 1-for-13 ratio is within the typical range for reverse stock splits, which can vary from 1-for-2 to 1-for-20 or more.

Stakeholder Impact

• Shareholders will see a reduction in the number of shares they own, but the value of their holdings should remain relatively constant immediately after the split.
• Shareholders holding fractional shares will receive a cash payment.
• The company's ability to raise capital may be affected by the reverse stock split.

Next Steps

• The reverse stock split will be effective on June 17, 2024.
• Shares will begin trading on a post-split basis on June 18, 2024.
• Stockholders holding physical stock certificates will receive instructions from the transfer agent.

Key Dates

Keywords

reverse stock split, Nasdaq compliance, common stock, GRI Bio, stock split, minimum bid price, biotechnology, NKT cell modulators